Advertisements



Hedge Funds Are Dumping Gilead Sciences, Inc. (GILD)

It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an invest.....»»

Category: topSource: insidermonkeyDec 7th, 2018

Bear of the Day: Gilead Sciences (GILD)

Zacks.....»»

Category: topSource: redinewsMar 18th, 2019

Gilead Sciences, Inc. (GILD) Presents at Barclays Global Healthcare Conference (Transcript)

Gilead Sciences, Inc. (GILD) Presents at Barclays Global Healthcare Conference (Transcript).....»»

Category: topSource: seekingalphaMar 12th, 2019

Stocks That Fell to 3-Year Lows in the Week of March 8

Gilead Sciences, CVS Health, Walgreens and Vodafone reach multiyear lowsRelated Stocks: GILD, CVS, WBA, VOD,.....»»

Category: personnelSource: nytMar 8th, 2019

Gilead Sciences Inc (GILD) Files 10-K for the Fiscal Year Ended on December 31, 2018

Related Stocks: GILD,.....»»

Category: smallbizSource: nytFeb 27th, 2019

Sofinnova Ventures Inc Buys NuCana PLC, Gilead Sciences Inc, Incyte Corp, Sells Ascendis Pharma ...

Related Stocks: NCNA, MOR, AZN, ACRS, FOLD, SRPT, GILD, BMRN, INCY, RETA, XN,.....»»

Category: smallbizSource: nytFeb 22nd, 2019

Analyst: Intercept"s NASH Drug Could Launch Sans Competition After Gilead Trial Failure

With Gilead Sciences, Inc. (NASDAQ: GILD)'s NASH setback, Intercept Pharmaceuticals, Inc. Latest Ratings for ICPT DateFirmActionFromT.....»»

Category: blogSource: benzingaFeb 13th, 2019

Dash for NASH trips up Gilead, but "fatty liver disease" remains biotech target

A late-stage clinical trial by Gilead Sciences Inc. failed in fatty liver disease, the company said, sending a blow to a drug industry that has seen treatments for the disease as the next big thing. The Foster City-based company's (NASDAQ: GILD) s.....»»

Category: topSource: bizjournalsFeb 12th, 2019

Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech

One of the three widely awaited clinical trial readouts from Gilead Sciences, Inc. (NASDAQ: GILD) turned out to be a disappointment, sending its shares down sharply Tuesday.  Latest Ratings for GILD.....»»

Category: blogSource: benzingaFeb 12th, 2019

Gilead"s Failed NASH Drug Trial Drags Stock Lower

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

Category: blogSource: benzingaFeb 12th, 2019

Why Gilead Sciences is a Top 25 Dividend Giant (GILD)

Dividend Channel.....»»

Category: topSource: redinewsFeb 7th, 2019

5 Top Stock Trades for Wednesday: GOOGL, GILD, EL, BA

Alphabet, Gilead Sciences and Estee Lauder all reported earnings. Starbucks and Boeing are breaking out. Here's our top stock trades......»»

Category: topSource: moneycentralFeb 5th, 2019

Analysts Focus On Gilead"s Late-Stage Data Readouts Following Mixed Q4

Gilead Sciences, Inc. (NASDAQ: GILD), which focuses on antiviral drugs, reported below-consensus fourth-quarter earnings per share Monday, sending its shares down.  Latest Rating.....»»

Category: blogSource: benzingaFeb 5th, 2019

2 Large-Cap Companies Report Earnings

Alphabet, Gilead Sciences move on financial resultsRelated Stocks: GOOG, GOOGL, GILD,.....»»

Category: blogSource: gurufocusFeb 5th, 2019

Gilead Sciences (GILD) Misses Q4 Earnings Estimates

Zacks.....»»

Category: topSource: redinewsFeb 5th, 2019

Gilead Sciences"(GILD) CEO Gregg Alton on Q4 2018 Results - Earnings Call Transcript

Gilead Sciences"(GILD) CEO Gregg Alton on Q4 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaFeb 4th, 2019

Why Gilead’s Disappointment Is Not Just an Earnings Story

Gilead Sciences, Inc. (NASDAQ: GILD) is living up to our theory behind the notion that Big Biotech is now effectively the same as Big Pharma. Gilead was soft on earnings and its shares were lower.........»»

Category: blogSource: 247wallstFeb 4th, 2019

Q4 Earnings Preview For Gilead Sciences

On Monday, Feb. 4, Gilead Sciences (NASDAQ: GILD) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Wall Street analysts see Gilead Scienc.....»»

Category: earningsSource: benzingaFeb 4th, 2019

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Zacks.....»»

Category: topSource: redinewsJan 8th, 2019

Hedge Funds Are Dumping Ethan Allen Interiors Inc. (NYSE:ETH)

Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing.....»»

Category: topSource: insidermonkeyDec 24th, 2018

Hedge Funds Are Dumping Cosan Limited (CZZ)

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quar.....»»

Category: topSource: insidermonkeyDec 23rd, 2018